Supply chain, compounding & pharmacy
Peptide API and fill-finish CDMOs, US 503B compounders and telehealth, direct-to-consumer pharmacies, and PBM formularies.
4 leading companies in supply chain, compounding & pharmacy, one segment of pharma: glp-1 & obesity drugs — Semaglutide, tirzepatide and the next wave: about $132B in 2025 GLP-1 sales, with generics now open in Canada
new market segment · researched 2026-11-14
GLP-1 diabetes drugsWeight-loss (obesity) injectablesOral GLP-1 pillsNext-generation obesity drugsGeneric semaglutideSupply chain, compounding & pharmacy
C
Leading supply chain, compounding & pharmacy companies
4 companies, with the scale each source states. Scale is the whole company's unless the row says otherwise.
| Company | Where | What they do | Scale |
|---|---|---|---|
| Catalent ↗ | Tampa, United States since 2007 | CDMO bought by Novo Holdings for $16.5B. Novo Nordisk took three Catalent plants for $11B to scale Wegovy/Ozempic output. | revenue: 4.38 USD billions (FY to 30 Jun 2024) (2024) ↗ |
| Bachem BANB.SW ↗ | Bubendorf, Switzerland since 1971 | Peptide API CDMO. Commercial API sales were CHF 343.4M in 2025, driven by 'patent-protected peptides'. The release does not name GLP-1 customers. | revenue: 695.1 CHF millions (2025) ↗ |
| Hims & Hers Health HIMS ↗ | San Francisco, United States since 2017 | Telehealth seller of compounded semaglutide since May 2024 (owns 503B MedisourceRx). Received an FDA warning letter Sep 2025. Novo sued over its compounded oral pill in Feb 2026. | revenue: 2.348 USD billions (total company) (2025) ↗ |
| CVS Health (CVS Caremark) CVS ↗ | Woonsocket, United States since 1963 | PBM. Made Wegovy preferred and removed Zepbound on its commercial template formularies from 1 Jul 2025 under a Novo deal. | — |
M
The pharma: glp-1 & obesity drugs market
The whole market this segment sits in.
global revenue · world132
↗USD billions (GLP-1 therapies, all indications) · 2025
Growth, segments, risks and every company in pharma: glp-1 & obesity drugs →
Quick answers
- What is supply chain, compounding & pharmacy?
- Peptide API and fill-finish CDMOs, US 503B compounders and telehealth, direct-to-consumer pharmacies, and PBM formularies. It is one segment of the pharma: glp-1 & obesity drugs market.
- Who are the leading supply chain, compounding & pharmacy companies?
- Catalent (United States), Bachem (Switzerland), Hims & Hers Health (United States), CVS Health (CVS Caremark) (United States).
- Which supply chain, compounding & pharmacy companies are publicly traded?
- Bachem (BANB.SW), Hims & Hers Health (HIMS), CVS Health (CVS Caremark) (CVS).
- How big is the pharma: glp-1 & obesity drugs market?
- For the whole pharma: glp-1 & obesity drugs market, not this segment alone: global revenue (world) 132 USD billions (GLP-1 therapies, all indications), 2025 — Managed Healthcare Executive.